BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 26081001)

  • 1. The antitumor effects of oncolytic adenovirus H101 against lung cancer.
    Lei J; Li QH; Yang JL; Liu F; Wang L; Xu WM; Zhao WX
    Int J Oncol; 2015 Aug; 47(2):555-62. PubMed ID: 26081001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of retinoblastoma in vitro and in vivo with conditionally replicating oncolytic adenovirus H101.
    Song X; Zhou Y; Jia R; Xu X; Wang H; Hu J; Ge S; Fan X
    Invest Ophthalmol Vis Sci; 2010 May; 51(5):2626-35. PubMed ID: 20007825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coxsackievirus and adenovirus receptor promotes antitumor activity of oncolytic adenovirus H101 in esophageal cancer.
    Ma J; Zhao J; Lu J; Jiang Y; Yang H; Li P; Zhao M; Liu K; Dong Z
    Int J Mol Med; 2012 Dec; 30(6):1403-9. PubMed ID: 22992863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced antitumor efficacy of telomerase-specific oncolytic adenovirus with valproic acid against human cancer cells.
    Watanabe Y; Hashimoto Y; Kagawa S; Kawamura H; Nagai K; Tanaka N; Urata Y; Fujiwara T
    Cancer Gene Ther; 2012 Nov; 19(11):767-72. PubMed ID: 22956040
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene therapy targeting hepatocellular carcinoma by a dual-regulated oncolytic adenovirus harboring the focal adhesion kinase shRNA.
    Gao Y; Zhu Y; Huang X; Ai K; Zheng Q; Yuan Z
    Int J Oncol; 2015 Aug; 47(2):668-78. PubMed ID: 26081241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recombinant oncolytic adenovirus H101 combined with siBCL2: cytotoxic effect on uveal melanoma cell lines.
    Huang X; Jia R; Zhao X; Liu B; Wang H; Wang J; Zhou Y; Cun B; Ge S; Fan X
    Br J Ophthalmol; 2012 Oct; 96(10):1331-8. PubMed ID: 22843987
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An oncolytic adenovirus enhances antiangiogenic and antitumoral effects of a replication-deficient adenovirus encoding endostatin by rescuing its selective replication in nasopharyngeal carcinoma cells.
    Liu RY; Zhou L; Zhang YL; Huang BJ; Ke ML; Chen JM; Li LX; Fu X; Wu JX; Huang W
    Biochem Biophys Res Commun; 2013 Dec; 442(3-4):171-6. PubMed ID: 24269822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of the coxsackie adenovirus receptor in neuroendocrine lung cancers and its implications for oncolytic adenoviral infection.
    Wunder T; Schmid K; Wicklein D; Groitl P; Dobner T; Lange T; Anders M; Schumacher U
    Cancer Gene Ther; 2013 Jan; 20(1):25-32. PubMed ID: 23196273
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Killing effect of TNF-mediated by conditionally replicating adenovirus on esophageal cancer and lung cancer cell lines.
    Jiang YQ; Zhang Z; Cai HR; Zhou H
    Int J Clin Exp Pathol; 2015; 8(11):13785-94. PubMed ID: 26823692
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibitor FR901228 enhances the antitumor effect of telomerase-specific replication-selective adenoviral agent OBP-301 in human lung cancer cells.
    Watanabe T; Hioki M; Fujiwara T; Nishizaki M; Kagawa S; Taki M; Kishimoto H; Endo Y; Urata Y; Tanaka N; Fujiwara T
    Exp Cell Res; 2006 Feb; 312(3):256-65. PubMed ID: 16356494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effect of CEA gene regulation on the anti-tumor activity of oncolytic adenovirus H101 to esophageal carcinoma].
    Zheng H; Li MS; Zhao GQ; Dong ZM
    Zhonghua Zhong Liu Za Zhi; 2011 Nov; 33(11):822-6. PubMed ID: 22335946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor suppressor in lung cancer-1 (TSLC1) mediated by dual-regulated oncolytic adenovirus exerts specific antitumor actions in a mouse model.
    Lei W; Liu HB; Wang SB; Zhou XM; Zheng SD; Guo KN; Ma BY; Xia YL; Tan WS; Liu XY; Wang YG
    Acta Pharmacol Sin; 2013 Apr; 34(4):531-40. PubMed ID: 23503473
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient antitumor effects of carrier cells loaded with a fiber-substituted conditionally replicating adenovirus on CAR-negative tumor cells.
    Iguchi K; Sakurai F; Tomita K; Katayama K; Yamaguchi T; Kawabata K; Tagawa M; Kawabata M; Shirakawa T; Mizuguchi H
    Cancer Gene Ther; 2012 Feb; 19(2):118-25. PubMed ID: 22076042
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel Golgi protein (GOLPH2)-regulated oncolytic adenovirus exhibits potent antitumor efficacy in hepatocellular carcinoma.
    Wang Y; Liu T; Huang P; Zhao H; Zhang R; Ma B; Chen K; Huang F; Zhou X; Cui C; Liu X
    Oncotarget; 2015 May; 6(15):13564-78. PubMed ID: 25980438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A vesicular stomatitis virus glycoprotein epitope-incorporated oncolytic adenovirus overcomes CAR-dependency and shows markedly enhanced cancer cell killing and suppression of tumor growth.
    Yoon AR; Hong J; Yun CO
    Oncotarget; 2015 Oct; 6(33):34875-91. PubMed ID: 26430798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined therapy of oncolytic adenovirus and temozolomide enhances lung cancer virotherapy in vitro and in vivo.
    Gomez-Gutierrez JG; Nitz J; Sharma R; Wechman SL; Riedinger E; Martinez-Jaramillo E; Sam Zhou H; McMasters KM
    Virology; 2016 Jan; 487():249-59. PubMed ID: 26561948
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncolytic Adenovirus H101 Synergizes with Radiation in Cervical Cancer Cells.
    Duan Y; Bai H; Li X; Wang D; Wang Y; Cao M; Zhang N; Chen H; Wang Y
    Curr Cancer Drug Targets; 2021; 21(7):619-630. PubMed ID: 33687882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced antitumor efficacy of fiber-modified, midkine promoter-regulated oncolytic adenovirus in human malignant mesothelioma.
    Takagi-Kimura M; Yamano T; Tamamoto A; Okamura N; Okamura H; Hashimoto-Tamaoki T; Tagawa M; Kasahara N; Kubo S
    Cancer Sci; 2013 Nov; 104(11):1433-9. PubMed ID: 23962292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined fiber modifications both to target α(v)β(6) and detarget the coxsackievirus-adenovirus receptor improve virus toxicity profiles in vivo but fail to improve antitumoral efficacy relative to adenovirus serotype 5.
    Coughlan L; Vallath S; Gros A; Giménez-Alejandre M; Van Rooijen N; Thomas GJ; Baker AH; Cascalló M; Alemany R; Hart IR
    Hum Gene Ther; 2012 Sep; 23(9):960-79. PubMed ID: 22708837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A capsid-modified, conditionally replicating oncolytic adenovirus vector expressing TRAIL Leads to enhanced cancer cell killing in human glioblastoma models.
    Wohlfahrt ME; Beard BC; Lieber A; Kiem HP
    Cancer Res; 2007 Sep; 67(18):8783-90. PubMed ID: 17875719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.